69
Participants
Start Date
June 14, 2023
Primary Completion Date
March 31, 2026
Study Completion Date
April 30, 2027
Bisphosphonate
Administered per investigator discretion via intravenous (IV) infusion
Setrusumab
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Nemours/ Alfred i. duPoint Hospital for Children, Wilmington
Children's National Hospital DC, Washington D.C.
University of North Carolina at Chapel Hill (UNC), Chapel Hill
University of South Florida, Tampa
Vanderbilt University Medical Center (VUMC), Nashville
Shriners Hospitals for Children Chicago, Chicago
Washington University School of Medicine, St Louis
Institut Imagine, Paris
Cook Children's Medical Center, Fort Worth
Baylor College of Medicine, Houston
Children's Hospital Colorado, Aurora
Phoenix Children's Hospital, Phoenix
Childrens Hospital LA, Los Angeles
Yale New Haven Hospital, New Haven
Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre
Children's Hospital at London Health Sciences Centre, London
Childrens Hospital Of Eastern Ontario Research Institute, University Of Ottawa, Ottawa
Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma
Universitair Medisch Centrum Utrecht (UMCU) - Wilhelmina Kinderziekenhuis, Utrecht
Uniwersytet Medyczny w Lodzi - Klinika Endokrynologii i Chorob Metabolicznych, Lodz
Ultragenyx Pharmaceutical Inc
INDUSTRY